TEST:

Decipher Prostate Cancer Test

A recent study published in JNCI Cancer Spectrum demonstrates the real-world utility of @Veracyte's #Decipher Prostate Genomic Classifier in #ProstateCancer treatment. #ReadNow details on UroToday > https://t.co/NOVWZFh6wC @JNCI_Now @DrSpratticus @Davicioni (@urotoday)

Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT (@urotoday)

Interesting addition to #radonc dose escalation in #ProstateCancer based on Decipher. Nice correlative science 🧬 by @DrSpratticus @jmmrad @felixfengmd @Davicioni @NRGonc (@TylerSbrt)

Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT (@urotoday)

Association between the #Decipher genomic classifier and #ProstateCancer outcome in a large-scale real-world dataset. Presented by @mleapman @Yale_Urology. #AUA23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Qk1PN6ICNR @AmerUrological @Decipher_VCYT (@urotoday)

Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT (@urotoday)

Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT ()

"Transcriptome-based prognostic and predictive biomarker analysis - The #DECIPHER Genomic Classifier for #ProstateCancer. @ashleyrossmdphd @NM_Urology joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/fsAE4fApYt @Decipher_VCYT" (@urotoday)

This video is going to be INCREDIBLY helpful to explain genomic testing to patients with #ProstateCancer. @Decipher_VCYT @PRIMR_MED @NRGonc @ASTRO_org @AmerUrological @UroOnc @ASCO https://t.co/r9vQkHaBLB ()

🆕As recently published in @IJROBP and featured on @QuadShotNews, this analysis of 3 RTOG trials led by @DrPaulNguyen found "The Decipher GC performed on pre-treatment biopsy specimens is prognostic of DM risk & survival in men receiving radiation for high risk prostate cancer" ()

👇👇 Check out the case study discussion on the role of decipher in #prostatecancer featuring our very own Dr. @ashleyrossmdphd! @urotoday ()

Validation of the performance of the #Decipher biopsy genomic classifier in intermediate-risk #ProstateCancer. @jmmrad @WUSTL discusses the phase III randomized trial NRG Oncology/RTOG 0126. Full video on UroToday > https://t.co/nDPeg2BqDr @Decipher_VCYT @Veracyte @DrSpratticus ()

Validation of the performance of the #Decipher biopsy genomic classifier in intermediate-risk #ProstateCancer: The phase III randomized trial NRG Oncology/RTOG 0126. Full video on UroToday > https://t.co/dRslNQhYRC @Decipher_VCYT @Veracyte @DrSpratticus @jmmrad @NRGOncology ()

High-risk #ProstateCancer and genomics. @DrPaulNguyen @DanaFarber & @_APollack @univmiami join @CaPsurvivorship in a discussion on risk prognostication in high-risk prostate cancer. #WatchNow on UroToday > https://t.co/fP5SEZYBH5 @BrighamWomens @decipher_bio ()

A systematic review of the Decipher® Genomic Classifier in #ProstateCancer. @ashleyrossmdphd & @DrSpratticus discuss this @EUplatinum publication showing consistent evidence that the test aids in personalized treatment decision-making > https://t.co/ab6Qc9Pbwd @Decipher_VCYT ()

Validation of the performance of the #Decipher Biopsy Genomic Classifier in intermediate-risk #ProstateCancer: the PIII randomized trial NRG Oncology/RTOG 0126. @jmmrad @WUSTL & @DrSpratticus @RadoncUh discuss on UroToday > https://t.co/ir60E91aPE @Decipher_VCYT @Veracyte @NRGonc ()

The impact of #Decipher biopsy testing on clinical outcomes in localized #ProstateCancer. @randy_vincejr @UMRogelCancer joins @DrSpratticus @cwru discuss recent work in this conversation on UroToday > https://t.co/LlTOiffhhK @Decipher_VCYT @Veracyte ()

Learn more about the "substantial benefit" of the @Decipher_VCYT test for patients with intermediate-risk prostate cancer from @UHhospitals @DrSpratticus https://t.co/NPutfI5uXN ()

Validation of the performance of the #Decipher biopsy genomic classifier in intermediate-risk #ProstateCancer in the phase III randomized trial NRG Oncology/RTOG 0126. Presented by @DrSpratticus. #GU22 written coverage by @WallisCJD on UroToday > https://t.co/7ipSdcWeZU @ASCO ()

Dr. Spratt on “substantial benefit” of Decipher test for patients with intermediate-risk prostate cancer https://t.co/C54CeN4t7b #GU22 #urology #urologist #prostatecancer @DrSpratticus ()

@UHhospitals @DrSpratticus presents @ASCO GU-Cancer Symposium study results validating the clinical utility of the Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer. https://t.co/FgBeicigFx @Veracyte @Decipher_VCYT ()

New data validates clinical utility of @Veracyte's #Decipher Prostate Genomic Classifier to help guide therapy in men with intermediate-risk #PCa. Data to be presented at @ASCO #GU22. #ReadNow for details > https://t.co/26sLGFODI0 @Decipher_VCYT @DrSpratticus @WallisCJD ()

High-risk #ProstateCancer and genomics. @DrPaulNguyen @DanaFarber & @_APollack @univmiami join @CaPsurvivorship in a discussion on risk prognostication in high-risk prostate cancer. #WatchNow on UroToday > https://t.co/fP5SEZYBH5 @BrighamWomens @decipher_bio ()

Listen to @UHhospitals @DrSpratticus & Dr. Randy Vince @UMich discuss the impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer. #prostatecancer https://t.co/ot9tgeXZW1 ()